

CHARLES G. MAHAKIAN, M.D.
BOARD CERTIFIED PSYCHIATRIST
6857 WEST CHARLESTON BLVD.
LAS VEGAS, NV 89117
702-258-6437

June 7, 2021

Silver State Script Board

State of Nevada, Department of Health and Human Services

Division of Health Care Financing and Policy (DHCFP)

1210 South Valley View Blvd Suite 104

Las Vegas, Nevada 89102

Re: SSSB Meeting for June 24, 2021, Psychotropic Agents-Antipsychotics-Atypical
Antipsychotics-Oral is item 6d on the agenda

I understand that there will be a review of Antipsychotics-Oral on the PDL at the June 24, 2021 Silver State Scripts Board. I would like to request that Caplyta (lumateperone) be available on the PDL as Preferred status for patient with Schizophrenia. I have initiated treatment with Caplyta and have had favorable response.

The once-a-day dosing, efficacy and side effect profile of this medication has been favorable. As you know efficacy and side effects differ from patient to patient so when prescribing medication providers must evaluate the side effect profile from agent to agent and determine which medication is best. Having Caplyta as a preferred would be beneficial and encourage compliance.

Sincerely,



Charles G. Mahakian M.D.